News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

University of California, Los Angeles (UCLA) Presents Data on MediciNova, Inc.'s MN-166 in Methamphetamine Addiction at the 75th Annual Meeting of the College on Problems of Drug Dependence


6/19/2013 9:40:22 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO, June 18, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced the presentation of preliminary results from a Phase 1b study of MN-166 (ibudilast) in methamphetamine addiction at the 75th Annual Meeting of the College on Problems of Drug Dependence (CPDD) in San Diego on June 18, 2013. MN-166 was featured in both a poster session and a symposium at the meeting where leading researchers discussed the role of activated glia, and potential intervention with glial attenuators like MN-166, in drug abuse. Pre-clinical and early clinical results were summarized in the symposium session.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   
Addiction

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES